Gastric Ulcer Treatment Market Size, Share and Global Trend By Drug class (Antibiotics, Antacids, H2 receptor antagonist, Anti-Histamines, Proton pump Inhibitor(PPIs)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Forecast, 2024-2032

Gastric ulcer occurs when the ability of mucosal lining of the stomach, small intestine or lower oesophagus, to resist the acidic digestive fluids gets reduced, which result in painful and open sore formation. Gastric ulcer drugs are used to treat the erosion of gastrointestinal lining due to a variety of factors. The most common cause of gastric ulcers is the growing rate of infection by Helicobacter pylori (H. pylori) bacteria, which is found in as many as half of us.

Other causes of gastric ulcers are extensive use of non-steroidal and anti-inflammatory drugs, lifestyle changes, and tobacco & alcohol consumption. According to Centre of Disease Control and Prevention (CDC), approximately two-thirds of the world’s population is infected by H. pylori. In the United States, around 500,000 to 850,000 people suffer from gastric ulcers every year. Furthermore, the growing prevalence of stress-induced ulcers due to increasing smoking rate, changing lifestyle and diet, and growing geriatric population are likely to promote the global gastric ulcer market growth during the forecast period.

Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that is found in the lining of the stomach and duodenum which produces urease, an enzyme that neutralizes the acid in the stomach by making it less acidic. H. pylori are likely to spread through food and water, and hence a large number of population is affected, leading to an increasing prevalence of H.pylori infections. Also, other major factors responsible for driving the gastric ulcer treatment market is extensive use of non-steroidal and anti-inflammatory drugs (NSAIDs) like Aspirin, Ibuprofen.

However, patent expiration of the peptic ulcer drugs and wide generic competition worldwide is declining the gastric ulcer treatment market size.

Key Players Covered

The major companies covered in the global gastric ulcer treatment market report are AstraZeneca, Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited, Aralez Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Actelion Pharmaceuticals Ltd., and Others.

SEGMENTATION 

As per the current gastric ulcer treatment market trends, antibiotics and antacids are the first line of gastric ulcers treatment caused by H. pylori bacterial infection and thus account for a major share in the global gastric ulcer treatment market.

Key Insights

• Pipeline analysis


• Patent analysis


• Gastric Ulcer Epidemiology – key countries,2018


• Overview of key industry developments


• Key mergers and acquisitions

Regional Analysis

Geographically, the gastric ulcer treatment market segments include North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for the highest share in terms of its revenue and is likely to show steady growth during the forecast period. In the U.S, approximately 4.5 million people are affected by peptic ulcer annually. Europe is the second-largest in the gastric ulcer treatment market. On the other hand, Asia Pacific is anticipated to register a higher CAGR during the forecast period owing to drastic lifestyle change, and increased number of H. pylori affected population. Additionally, the Latin America and Middle East & Africa market account for a smaller market share in the global gastric ulcer treatment market owing to lack of penetration of gastric ulcer drugs in the regions.

Key Industry Developments

• In April 2018, AstraZeneca and Daiichi Sankyo Inc. launched proton pump inhibitor NEXIUM for eradication of H. pylori in the treatment of gastric ulcer infections.
• In September 2016, Aralez Pharmaceuticals Inc. received FDA approval to market YOSPRALA, a combination of aspirin and omeprazole, a proton pump inhibitor for the treatment of gastric ulcers.
• In February 2016, FDA granted marketing approval to TAKECAB tablet, developed by Takeda for eradication of H. pylori in the treatment of gastric ulcer infections.